The Centers for Medicare & Medicaid Services today issued a proposed rule setting forth a bundled payment model for radiation oncology, which would be mandatory in certain areas of the country. Under the model, participants would receive a bundled payment for 90-day episodes of radiation therapy for 17 disease sites, including breast, lung, prostate, kidney and colorectal cancer. This bundled payment would be made instead of regular Medicare fee-for-service payments; providers would keep any savings if spending is less than the bundled payment, subject to quality and patient experience measures, but also would be responsible for any spending above the payment amount. In addition, the model is designed to be site-neutral — that is, the bundled payment amount is designed to be calculated similarly regardless of whether the provider is a physician, hospital outpatient department or non-hospital setting. CMS proposes to run the model for five years, beginning either Jan. 1 or April 1, 2020. The proposed rule is expected to be published in the Federal Register soon, and CMS will accept comment for 60 days after publication. 

Related News Articles

Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
The Department of Health and Human Services’ Advanced Research Projects Agency (ARPA-H) has released a draft solicitation for applicants to the Health Care…
Headline
The Centers for Medicare & Medicaid Services expects to launch a voluntary primary care model in January 2025 for low-revenue accountable care…
Headline
AHA March 18 shared with the House Ways and Means Committee its proposals to strengthen access to timely emergency medical care, particularly in rural and…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…